Opinion|Videos|August 21, 2024
CML Treatment: Scenarios that Necessitate Switching Therapy
Jorge E. Cortes, MD, details clinical scenarios that indicate a need to switch therapies for patients with chronic myeloid leukemia.
Advertisement
Episodes in this series
This program was made possible with support from Novartis Pharmaceuticals.
Video content above is prompted by the following:
- In which scenarios do you consider switching CML therapies, and how do you approach that conversation with patients? How does the patient experience change when switching therapies?
Advertisement
Related to this article
Up to 40% of patients with classic hairy cell leukemia relapse within 10 to 15 years. An NIH researcher explains how adding Rituxan up front may help.
A new trial will test whether a set course of Brukinsa plus sonrotoclax, which target two pathways that drive hairy cell leukemia, can offer an alternative to chemotherapy.
An experimental treatment has kept one patient with heavily pretreated hairy cell leukemia free of detectable disease for more than two years, raising questions about whether CAR T-cell therapy could offer a path toward a cure.
Advertisement
Advertisement
Trending on CURE
1
What Is a Whipple Procedure? Pancreatic Cancer Surgery Explained
2
Datroway Slows Brain Metastases in Triple-Negative Breast Cancer
3
Weight Loss With Pancreatic Cancer: Why It Happens and What Helps
4
Glioblastoma Patients Can Request Genomic Testing on Their Tumor Tissue
5